XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
US Stock MarketDetailed Quotes
ADVM Adverum Biotechnologies
- 4.4600
- +0.1700+3.96%
Close Feb 14 16:00 ET
- 4.4600
- 0.00000.00%
Post 20:01 ET
92.78MMarket Cap-0.75P/E (TTM)
4.4800High4.2300Low82.51KVolume4.3100Open4.2900Pre Close364.99KTurnover0.73%Turnover RatioLossP/E (Static)20.80MShares22.400052wk High0.64P/B50.78MFloat Cap3.845052wk Low--Dividend TTM11.39MShs Float624.8000Historical High--Div YieldTTM5.83%Amplitude3.8450Historical Low4.4230Avg Price1Lot Size
Trending Stocks
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call
Adverum Biotechnologies Stock Forum
📊⚡️📊
Adverum Biotechnologies Announces FDA Regenerative Medicine Advanced Therapy (Rmat) Designation Granted for Ixo-Vec for the Treatment of Wet AMD
Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting
Adverum Biotechnologies (Nasdaq: ADVM) presented positive 26-week interim results from the LUNA Phase 2 trial of Ixo-vec for wet AMD at the 2024 ASRS Annual Meeting. Key findings include:
1. The 6E10 dose with local prophylaxis was selected for Phase 3 trials.
2. 76% of 6E10 patients were injection-fr...
NEWS
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting
4 MINUTES AGO, 7:00 AM EST
VIA GLOBENEWSWIRE
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and anatomic endpoints –
– Preliminary safety data support a favorable benefit-risk pr...
Just I am afriad the 1.2 private offering deal (typically 20% to 10% off to fair value) will pin the price to 1.4 to 1.6 area. Cashless warrant is bad for common investors. Also attract too many day traders. won’t last l...
$EyePoint Pharmaceuticals (EYPT.US)$
$Adverum Biotechnologies (ADVM.US)$
$Regenxbio (RGNX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Kodiak Sciences (KOD.US)$
No comment yet